Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis - 21/08/11
Atlanta, Georgia
Abstract |
Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin. Corticosteroids are the mainstay of therapy of dermatomyositis, and severe morbidity and mortality occurs in part through the known long-term side effects of chronic steroid use. In addition, dermatomyositis is commonly associated with underlying malignancy, and high-dose steroids may adversely impair treatment of these malignancies. We describe the first use of rapamycin in a young patient with dermatomyositis.
Le texte complet de cet article est disponible en PDF.Plan
This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology. Funding sources: None. Conflicts of interest: None identified. |
Vol 52 - N° 2S
P. S17-S19 - février 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?